share_log

Needham Reiterates Buy on TransMedics Gr, Maintains $208 Price Target

Benzinga ·  Aug 23 18:23  · Ratings

Needham analyst Mike Matson reiterates TransMedics Gr (NASDAQ:TMDX) with a Buy and maintains $208 price target.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment